| 000 | 00906 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250515074457.0 | ||
| 264 | 0 | _c20070821 | |
| 008 | 200708s 0 0 eng d | ||
| 022 | _a1540-658X | ||
| 024 | 7 |
_a10.1089/adt.2007.9992 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJohnston, Paul A | |
| 245 | 0 | 0 |
_aAn interview with Paul A. Johnston, Ph.D., by Vicki Glaser. _h[electronic resource] |
| 260 |
_bAssay and drug development technologies _cJun 2007 |
||
| 300 |
_a289-97 p. _bdigital |
||
| 500 | _aPublication Type: Interview | ||
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 |
_aDrug Evaluation, Preclinical _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMAP Kinase Signaling System _xdrug effects |
| 650 | 0 | 4 | _aMicroscopy |
| 773 | 0 |
_tAssay and drug development technologies _gvol. 5 _gno. 3 _gp. 289-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/adt.2007.9992 _zAvailable from publisher's website |
| 999 |
_c17172881 _d17172881 |
||